Hannover Medical School (MHH) reported a scalable method to turn induced pluripotent stem cells into immune-cell factories using medium-sized bioreactors. In Nature Protocols, the team described production of roughly 40 million human macrophages per week. The paper details a process designed for efficient generation of macrophages for disease research and therapeutic development. Because macrophages are central to inflammation, infection, and tumor microenvironments, high-throughput production can accelerate preclinical modeling and help standardize cell sourcing. For the field of cell therapy and translational immunology, the practical constraint is often not only differentiating the correct lineage but doing so with reproducible yields and manageable manufacturing complexity. By publishing a protocol aimed at operational scale, MHH’s work may reduce friction for labs and developers that need macrophage material for functional assays, translational studies, and platform screening.